The clinical effects of the BiodivYsio Phosphorylcholine-coated Stent in patients with small coronary artery diseases.
- Author:
Young Joon HONG
1
;
Myung Ho JEONG
;
Doo Sun SHIM
;
Sang Yup LIM
;
Bo Ra YANG
;
Sang Hyun LEE
;
Seung Hyun LEE
;
Ok Young PARK
;
Woo Seok PARK
;
Joo Han KIM
;
Myung Ja CHOI
;
In Soo KIM
;
Weon KIM
;
Young Keun AHN
;
Jeong Gwan CHO
;
Jong Chun PARK
;
Jung Chaee KANG
Author Information
1. The Heart Center of Chonnam National University Hospital, Chonnam National University, Gwangju, Korea. myungho@chollian.net
- Publication Type:Original Article
- Keywords:
Coronary artery diseases;
Percutaneous coronary intervention;
Restenosis;
Balloon;
Stents
- MeSH:
Angioplasty, Balloon;
Coronary Angiography;
Coronary Artery Disease*;
Coronary Vessels*;
Follow-Up Studies;
Hospitalization;
Humans;
Incidence;
Male;
Myocardial Infarction;
Percutaneous Coronary Intervention;
Phosphorylcholine;
Prospective Studies;
Stents*;
Thrombosis
- From:Korean Journal of Medicine
2002;63(3):251-260
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: The BiodivYsio stent is a balloon-expandable stent coated with phosphorylcholine designed to reduce the formation of thrombus and the risk of restenosis. METHODS: We prospectively studied 20 patients who underwent implantation of BiodivYsio stent (group I; 60.8+/-9.3 years, male 60.0%) and compared to 20 patients who underwent balloon angioplasty alone (group II; 60.3+/-7.9 years, male 45.0%) for small coronary arterial lesions (target arterial diameter was between 2.0 mm and 2.8 mm) between February 2001 and October 2001. Major adverse cardiac events such as acute myocardial infarction, target vessel revascularization and death were evaluated during hospital admission and at 6-months after percutaneous coronary intervention (PCI). RESULTS: During hospitalization, the incidence of acute myocardial infarction, target vessel revascularization and death was not different between the two groups. At follow-up coronary angiography 6 months after PCI, the incidence of restenosis was lower in group I than in group II (Group I; 3/20, 15.0% vs Group II; 9/20, 45.0%, p=0.032) and the incidence of target vessel revascularization (TLR) was lower in group I than in group II (Group I; 3/20, 15.0% vs Group II; 8/20, 40.0%, p=0.041). CONCLUSION: Coronary BiodivYsio stenting in small coronary artery leads to excellent short- and mid-term clinical outcomes.
